Research field (1)：
Pharmaceuticals - health and biochemistry
Research theme for competitive and other funds (2)：
2024 - 2027 miRNAに着目したPPARγ依存的な非アルコール性脂肪肝発症機構の解明
2022 - 2024 モルヒネ代謝物モルヒノンに着目したモルヒネ鎮痛耐性メカニズムの解明
Papers (10)：
Kohei Matsuo, Shigeru Yamano, Akira Toriba, Kimihiko Matsusue, Yoshito Kumagai, Yumi Abiko. Activation of Akt-cAMP response element-binding protein (CREB) signaling as an adaptive response to an electrophilic metabolite of morphine. Fundamental Toxicological Sciences. 2024. 11. 2. 79-85
Kohei Matsuo, Yumi Abiko, Shigeru Yamano, Kimihiko Matsusue, Yoshito Kumagai. Activation of HSP90/HSF1 Signaling as an Adaptive Response to an Electrophilic Metabolite of Morphine. Biological & pharmaceutical bulletin. 2023. 46. 2. 334-337
Kohei Matsuo, Yumi Abiko, Shigeru Yamano, Akira Toriba, Kimihiko Matsusue, Yoshito Kumagai. Activation of the Keap1/Nrf2 Pathway as an Adaptive Response to an Electrophilic Metabolite of Morphine. Biological & pharmaceutical bulletin. 2023. 46. 2. 338-342
Daisuke Aibara, Kohei Matsuo, Kimihiko Matsusue. Lipase family member N is a novel target gene for CCAAT/enhancer-binding protein α in type 2 diabetic model mouse liver. Endocrine journal. 2022. 69. 5. 567-575
